We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
- Authors
Sonpavde, G; Periman, P O; Bernold, D; Weckstein, D; Fleming, M T; Galsky, M D; Berry, W R; Zhan, F; Boehm, K A; Asmar, L; Hutson, T E
- Abstract
Systemic therapy options are limited for metastatic castration-resistant prostate cancer (CRPC) patients who progress following docetaxel (Taxotere). This phase II trial evaluated sunitinib malate in patients with progressing metastatic CRPC following prior docetaxel.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Vol 21, Issue 2, p319
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mdp323